Amundi’s Prime Medicine PRME Stock Holding History

Amundi’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,770	Closed	-$106K	–	2062
2023 Q4	$106K	Buy	+11,770	New	+$90.7K	﹤0.01%	1767

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Amundi's PRME Position: Q1 2024 in Review

Amundi sold out of Prime Medicine (PRME) in Q1 2024, closing a stake of 11,770 shares — an estimated $106K sold.

Amundi first reported a position in PRME in Q4 2023 and held it in 1 quarter. The position peaked at $106K in Q4 2023. 115 funds tracked by Wall St. Rank hold PRME as of Q1 2024.

Amundi reported no remaining Prime Medicine position as of Q1 2024 after selling out during the quarter.
Amundi sold 11,770 Prime Medicine shares in Q1 2024, an estimated $106K.
Amundi first reported a position in Prime Medicine in Q4 2023 and held it in 1 quarter.
Amundi's Prime Medicine position peaked at $106K in Q4 2023.
115 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2024.

Based on Amundi's 13F filing for Q1 2024, filed 15 May 2024.